When Patents Expire, Wars Begin The Semaglutide Story
Patent expiry creates price wars, but complex drugs and innovation cycles decide long-term winners, not just early generic advantage.
One morning, a ₹10,000 drug became ₹1,300.
Not because companies became generous — but because the patent clock ran out.
On March 20, semaglutide’s patent expired in India. Within days, multiple Indian pharma players rushed in. Prices crashed nearly 90%. Access expanded overnight.
This is India’s classic playbook: wait, copy, scale, dominate.
But this time, the game isn’t simple.
Semaglutide is not like aspirin. It’s a complex peptide with hundreds of atoms, requiring precision manufacturing, high-cost purification, and advanced infrastructure. Even small errors can change how the drug behaves in the human body.
So while many companies entered, execution—not entry—is the real challenge.
Meanwhile, the global story is different. The biggest markets (US, Europe) remain under patent protection until 2032. And innovators have already moved ahead with better drugs like dual-hormone therapies.
This creates a two-layer market:
India: price war, volume game
Global: innovation, premium pricing
Stocks from Nifty 500 benefiting from this trend:
Sun Pharmaceutical Industries
Dr. Reddy’s Laboratories
Cipla